

## DAFTAR PUSTAKA

- Amyes, S. (2010) Oxford Infectious Disease Library : Antimicrobial Chemotherapy. New York: Oxford University Press Inc
- Anggraini, D. 2018. Prevalensi dan pola sensitivitas antimikroba Multidrug resistant *Pseudomonas aeruginosa* di RSUD Arifin Achmad (Disertasi). Fakultas kedokteran bagian mikrobiologi. Universitas Riau/RSUD Arifin Achmad. Pekanbaru.
- Alzahmi A, 2015. 'Pseudomonas aeruginosa-Pathogenesis and Pathogenic Mechanisms'. *Int. J. Bio.* 7(2): 44-67.
- Avrain, L., Mertens, P., and Van Bambeke, F. (2013). RND efflux pumps in *P. aeruginosa*: an underestimated resistance mechanism. *Antibiot. Susceptibility* 26321, 26–28. Available online at: <http://www.uclouvain.be/cps/ucl/doc/ir-ldri/images/Avrain-2013-1.pdf>
- Barclay, M. L., Begg, E. J., and Chambers, S. T. (1992). Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. *Antimicrob. Agents Chemother.* 36, 1951–1957. doi: 10.1128/AAC.36.9.1951
- Baumgart, A. M., Molinari, M. A., and Silveira, A. C. (2010). Prevalence of carbapenem resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* in high complexity hospital. *Braz. J. Infect. Dis.* 14, 433–436. doi: 10.1590/S1413-86702010000500002
- Berrazeg, M., Jeannot, K., Ntsogo Enguene, V. Y., Broutin, I., Loeffert, S., Fournier, D., et al. (2015). Mutations in b-lactamase AmpC increase resistance of *Pseudomonas aeruginosa* isolates to antipseudomonal cephalosporins. *Antimicrob. Agents Chemother.* 59, 6248–6255. doi: 10.1128/AAC.00825-15
- Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O., and Piddock, L. J. (2015). Molecular mechanisms of antibiotic resistance. *Nat. Rev. Microbiol.* 13, 42–51. doi: 10.1038/nrmicro3380
- Carroll KC, Hobden JA, Miller S, Morse SA, Mietzner TA, Detrick B, Mitchell , Mckerrow JH, and Sakanari JA, 2013. 'Medical Microbiology'. 27th ed. New York: Mc Graw Hill: 245-248
- CDC (2013) 'Antibiotic resistance threats in the United States, 2013', *Current*, p. 114. doi: CS239559-B.
- CLSI (2010). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement. CLSI Document M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute.

- CLSI (2017). Performance Standards for Antimicrobial Susceptibility Testing CLSI Supplement M100, 27th Edn. Wayne, PA: Clinical and Laboratory Standards Institute.
- DePestel, D. and Paterson, D. (2010) 'Doripenem', in Grayson, M. (ed.) *Kucers' The Use Of Antibiotics*. 6th edn. London: Edward Arnold(Publisher) Ltd, pp.515–525.
- Dortet L, Boulanger A, Poirel L, Nordmann P. Bloodstream infections caused by *Pseudomonas* spp.; how to detect carbapenemase producers directly from positive blood cultures?. *Journal of clinical microbiology*. 2014; JCM-03346.
- El Amin, N., Giske, C. G., Jalal, S., Keijsers, B., Kronvall, G., and Wretling, B. (2005). Carbapenem resistance mechanisms in *Pseudomonas aeruginosa*: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. *APMIS* 113, 187–196. doi: 10.1111/j.1600-0463.2005.apm1130306.x
- Eurosurveillance Editorial Team (2013). CDC publishes report on antibiotic resistance threats in the United States for the first time. *Eurosurveillance* 18:5. Available online at : <http://www.ecdc.europa.eu/en/activities/sciadvices/layouts/forms/ReviewDispForm.aspx?List=a3216f4c-f040-4f51-9f77a96046dbfd72&ID=752&RootFolder=%2Fen%2Factivities%2Fsciadvices%2FList%2FECDC%20Reviews&Web=0be238ef-4498-4962-8826-2e082a1f1639>
- Epp, S. F., Köhler, T., Plésiat, P., Michéa-Hamzehpour, M., Frey, J., and Pechère, J. C. (2001). C-terminal region of *Pseudomonas aeruginosa* outer membrane porin OprD modulates susceptibility to meropenem. *Antimicrob. Agents Chemother.* 45, 1780–1787. doi: 10.1128/AAC.45.6.1780-1787.2001
- Fernández-García, L., Blasco, L., Lopez, M., Bou, G., García-Contreras, R., Wood, T., et al. (2016). Toxin-antitoxin systems in clinical pathogens. *Toxins (Basel)*. 8:227. doi: 10.3390/toxins8070227
- Fujimura, T., Anan, N., Sugimori, G., Watanabe, T., Jinushi, Y., Yoshida, I., et al. (2009). Susceptibility of *Pseudomonas aeruginosa* clinical isolates in Japan to doripenem and other antipseudomonal agents. *Int. J. Antimicrob. Agents* 34, 523–528. doi: 10.1016/j.ijantimicag.2009.07.008
- Frimmersdorf, E., Horatzek, S., Pelnikovich, A., Wiehlmann, L., and Schomburg, D. (2010). How *Pseudomonas aeruginosa* adapts to various environments: a metabolomic approach. *Environ. Microbiol.* 12, 1734–1747. doi: 10.1111/j.1462-2920.2010.02253.x
- Govan JRV, 2012. 'Pseudomonas and non-fermenters. Opportunistic infection, Cystic fibrosis, Melioidosis. In Greenwood D, Barer M, Slack R, Irving W. *Medical microbiology, A guide to Microbial Infections: Pathogenesis, Immunity, Laboratory investigation and Control*. Churchill Livingstone Elsevier. 18th ed. Pp. 298-302.
- Gutiérrez, O., Juan, C., Cercenado, E., Navarro, F., Bouza, E., Coll, P., et al. (2007). Molecular epidemiology and mechanisms of carbapenem resistance in

- Pseudomonas aeruginosa* isolates from Spanish hospitals. *Antimicrob. Agents Chemother.* 51, 4329–4335. doi: 10.1128/AAC.00810-07
- Hammond, M. L. (2004) ‘Ertapenem: A group 1 carbapenem with distinct antibacterial and pharmacological properties’, *Journal of Antimicrobial Chemotherapy*, 53(SUPPL. 2), pp. 7–10. doi: 10.1093/jac/dkh203.
- Hancock, R. E.W., and Speert, D. P. (2000). Antibiotic resistance in *Pseudomonas aeruginosa*: mechanisms and impact on treatment. *Drug Resist Updat.* 3, 247–255. doi: 10.1054/drup.2000.0152
- Hall GS, 2015. ‘Nonfermenting and Miscellaneous Gram Negative Bacilli. In Mahon CR, Lehman DC, Manuselis G *Textbook of Diagnostic Microbiology*. 5th ed. Maryland: Saunders Elsevier. Pp.475-483
- Hayashi, Y. and Paterson, D. (2010) ‘Carbapenem’, in Grayson, M. (ed.) *Kucers’ The Use Of Antibiotics*. 6th edn. London: Edward Arnold(Publisher) Ltd, pp. 471–492.
- Henrichfreise, B., Wiegand, I., Pfister, W., and Wiedemann, B. (2007). Resistance mechanisms of multiresistant *Pseudomonas aeruginosa* strains from Germany and correlation with hypermutation. *Antimicrob. Agents Chemother.* 51, 4062–4070. doi: 10.1128/AAC.00148-07
- Jean, S. S., Lee, W. S., Lam, C., Hsu, C. W., Chen, R. J., and Hsueh, P. R. (2015). Carbapenemase-producing gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options. *Future Microbiol.* 10, 407– 410
- Jeon, J. H., Lee, J. H., Lee, J. J. et al. (2015) ‘Structural basis for carbapenemhydrolyzing mechanisms of carbapenemases conferring antibiotic resistance’, *International Journal of Molecular Sciences*, 16(5), pp. 9654–9692. doi: 10.3390/ijms16059654.
- Jing X, Zhou H, Min X, Zhang X, Yang Q, Du S, Li Y, Yu F, Jia M, Zhan Y, Zeng Y, Yang B, Pan Y, Lu B, Liu R and Zeng J (2018) The Simplified Carbapenem Inactivation Method (sCIM) for Simple and Accurate Detection of Carbapenemase-Producing Gram-Negative Bacilli. *Front. Microbiol.* 9:2391. doi: 10.3389/fmicb.2018.02391 425. doi: 10.2217/fmb.14.135
- Juan, C., Macia, M. D., Gutierrez, O., Vidal, C., Perez, J. L., and Oliver, A. (2005). Molecular mechanisms of b-lactam resistance mediated by AmpC hyperproduction in *Pseudomonas aeruginosa* clinical strains. *Antimicrob. Agents Chemother.* 49, 4733–4738. doi: 10.1128/AAC.49.11.4733-4738.2005
- Kao, C. Y., Chen, S. S., Hung, K. H., Wu, H. M., Hsueh, P. R., Yan, J. J., et al. (2016). Overproduction of active efflux pump and variations of OprD dominate in imipenem-resistant *Pseudomonas aeruginosa* isolated from patients with bloodstream infections in Taiwan. *BMC Microbiol.* 16:107. doi: 10.1186/s12866-016-0719-2
- Khaleedi, A., Schniederjans, M., Pohl, S., Rainer, R., Bodenhofer, U., Xia, B., et al. (2016). Transcriptome profiling of antimicrobial resistance in *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 60, 4722–4733. doi: 10.1128/AAC.00075-16

- Kuntaman, Shigemura, et al, 2018. Occurrence and characterization of carbapenem-resistant Gram-negative bacilli: A collaborative study of antibiotic-resistant bacteria between Indonesia and Japan. *International Journal of Urology*. Kobe University. doi:10.1111/iju.13787
- Köhler, T., van Delden, C., Curty, L. K., Hamzehpour, M. M., and Pechere, J. C. (2001). Overexpression of the MexEF-OprN multidrug efflux system affects cell-to-cell signaling in *Pseudomonas aeruginosa*. *J. Bacteriol.* 183, 5213–5222. doi: 10.1128/JB.183.18.5213-5222.2001
- Lambert, M. L., Suetens, C., Savey, A., Palomar, M., Hiesmayr, M., Morales, I., et al. (2011). Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. *Lancet Infect. Dis.* 11, 30–38. doi: 10.1016/S1473-3099(10)70258-9
- Lee, J. Y., Park, Y. K., Chung, E. S., Na, I. Y., and Ko, K. S. (2016). Evolved resistance to colistin and its loss due to genetic reversion in *Pseudomonas aeruginosa*. *Sci. Rep.* 6:25543. doi: 10.1038/srep25543
- Leboffe J Michael., 2011, *A Photographic Atlas for the Microbiology Laboratory*, 4th ed, Colorado, Morton Publishing, pp. 15, 24.
- Logan, L. K., and Weinstein, R. A. (2017). The epidemiology of Carbapenem resistant Enterobacteriaceae: the impact and evolution of a global menace. *J. Infect. Dis.* 215, S28–S36. doi: 10.1093/infdis/jiw282
- Li, X. Z., Plésiat, P., and Nikaido, H. (2015). The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. *Clin. Microbiol. Rev.* 28, 337–418. doi: 10.1128/CMR.00117-14
- Lister, P. D., Wolter, D. J., and Hanson, N. D. (2009). Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin. Microbiol. Rev.* 22, 582–610. doi: 10.1128/CMR.00040-09
- Llanes, C., Kohler, T., Patry, I., Dehecq, B., van Delden, C., and Plésiat, P. (2011). Role of the MexEF-OprN efflux system in low-level resistance of *Pseudomonas aeruginosa* to ciprofloxacin. *Antimicrob. Agents Chemother.* 55, 5676–5684. doi: 10.1128/AAC.00101-11
- Mathee, K., Narasimhan, G., Valdes, C., Qiu, X., Matewish, J. M., Koehrsen, M., et al. (2008). Dynamics of *Pseudomonas aeruginosa* genome evolution. *Proc. Natl. Acad. Sci. U.S.A.* 105, 3100–3105. doi: 10.1073/pnas.0711982105
- Mesaros N, et al. 2007. *Pseudomonas aeruginosa*: resistance and therapeutic options at the turn of the new millennium. *Clin. Microbiol. Infect.* 13:560–578.
- Moradali MF, Ghods S and Rehm BHA (2017) *Pseudomonas aeruginosa* Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. *Front. Cell. Infect. Microbiol.* 7:39. doi: 10.3389/fcimb.2017.00039

- Mouneimné, H., Robert, J., Jarlier, V., and Cambau, E. (1999). Type II topoisomerase mutations in ciprofloxacin-resistant strains of *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 43, 62–66.
- Ochs, M. M., McCusker, M. P., Bains, M., and Hancock, R. E. (1999). Negative regulation of the *Pseudomonas aeruginosa* outer membrane porin OprD selective for imipenem and basic amino acids. *Antimicrob. Agents Chemother.* 43, 1085–1090.
- Othman HB, Abdel Halim RM, Abdul Wahab HEE, Abol Atta H, Shaaban O. *Pseudomonas aeruginosa* – Modified Hodge Test (PAE-MHT) and ChromID Carba Agar for Detection of carbapenemase Producing *Pseudomonas aeruginosa* Recovered from Clinical Specimens. *Open Access Maced J Med Sci.* 2018 Dec 20;6(12):2283-2289.
- Oliver, A., Mulet, X., López-Causapé, C., and Juan, C. (2015). The increasing threat of *Pseudomonas aeruginosa* high-risk clones. *Drug Resist. Updat.* 21–22, 41–59. doi: 10.1016/j.drug.2015.08.002
- Pagedar, A., Singh, J., and Batish, V. K. (2011). Efflux mediated adaptive and cross resistance to ciprofloxacin and benzalkonium chloride in *Pseudomonas aeruginosa* of dairy origin. *J. Basic Microbiol.* 51, 289–295. doi: 10.1002/jobm.201000292
- Peleg, A. and Salmon, M. (2010) ‘Meropenem’, in Grayson, M. (ed.) *Kucers’ The Use Of Antibiotics.* 6th edn. London: Edward Arnold(Publisher) Ltd, pp. 500– 510.
- Peleg, A. Y. and Hooper, D. C. (2010) ‘Hospital-Acquired Infections Due to Gram-Negative Bacteria’, *New England Journal of Medicine*, 362(19), pp. 1804– 1813. doi: 10.1056/NEJMra0904124.
- Pierce, V. M., Simner, P. J., Lonsway, D. R., Roe-Carpenter, D. E., Johnson, J. K., Brasso, W. B., et al. (2017). The modified carbapenem inactivation Method (mCIM) for phenotypic detection of carbapenemase production among Enterobacteriaceae. *J. Clin.Microbiol.* 55, 2321–2333. doi: 10.1128/JCM. 00193-17
- Poole, K. (2005). Aminoglycoside resistance in *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 49, 479–487. doi: 10.1128/AAC.49.2.479-487.2005
- Potron, A., Poirel, L., and Nordmann, P. (2015). Emerging broad-spectrum resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii*: mechanisms and epidemiology. *Int. J. Antimicrob. Agents* 45, 568–585. doi: 10.1016/j.ijantimicag.2015.03.001
- Quale, J., Bratu, S., Gupta, J., and Landman, D. (2006). Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of *Pseudomonas aeruginosa* clinical isolates. *Antimicrob. Agents Chemother.* 50, 1633–1641. doi: 10.1128/AAC.50.5.1633-1641.2006
- Radji Maksum.,(2014). *Mekanisme aksi molekuler.Antibiotik dan kemoterapi.*EGC.Jakarta. hal. 2-10
- Retamar, P. (2010) ‘Ertapenem’, in Grayson, M. (ed.) *Kucers’ The Use Of Antibiotics.* 6th edn. London: Edward Arnold(Publisher) Ltd, p. 527.

- Rodloff, A. C., Goldstein, E. J. and Torres, A. (2006) 'Two decades of imipenem therapy.', *J Antimicrob Chemother*, 58(5), pp. 916–29. doi: 10.1093/jac/dkl354.
- Shah, P. M. and Isaacs, R. D. (2003) 'Ertapenem, the first of a new group of carbapenems', *Journal of Antimicrobial Chemotherapy*, 52(4), pp. 538–542. doi: 10.1093/jac/dkg404.
- Soedarto. 2016. *Infeksi nosokomial di rumah sakit*. 1th ed. Sagung seto. Surabaya. Hal. 233-240.
- Stover, C. K., Pham, X. Q., Erwin, A. L., Mizoguchi, S. D., Warrener, P., Hickey, M. J., et al. (2000). Complete genome sequence of *Pseudomonas aeruginosa* PAO1, an opportunistic pathogen. *Nature* 406, 959–964. doi: 10.1038/35023079
- Strateva, T., and Yordanov, D. (2009). *Pseudomonas aeruginosa* – a phenomenon of bacterial resistance. *J. Med. Microbiol.* 58, 1133–1148. doi: 10.1099/jmm.0.009142-0
- Tamber, S., and Hancock, R. E. (2003). On the mechanism of solute uptake in *Pseudomonas*. *Front. Biosci.* 8:s472–s483. doi: 10.2741/1075
- Tille PM, 2014. 'Diagnostic Microbiology'. 13 th ed. Missouri: Elsevier Inc. Pp. 335-347
- Trias, J., and Nikaido, H. (1990). Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 34, 52–57. doi: 10.1128/AAC.34.1.52
- Todar K. 2011. Online textbook of Bacteriology. <http://textbookofbacteriology.net/pseudomonas.html>(2 november 2011)
- Veesenmeyer J, Hauser A, Lisboa T, and Rello , 2010. 'Pseudomonas aeruginosa Virulence and Therapy: Evolving Translational Strategies'. *Crit Care Med.*37(5): 1777-86.
- Venter, H., Mowla, R., Ohene-Agyei, T., and Ma, S. (2015). RND-type drug e fflux pumps from Gram-negative bacteria: molecular mechanism and inhibition. *Front. Microbiol.* 6:377. doi: 10.3389/fmicb.2015.00377
- Wasito, Bagus Eddy., 2002, *Bakteriologi Kedokteran* , ed 1, Surabaya, Pusat Penerbitan dan Percetakan UNAIR, hal. 1-25.
- Xiong, Y. Q., Caillon, J., Drugeon, H., Potel, G., and Baron, D. (1996). Influence of pH on adaptive resistance of *Pseudomonas aeruginosa* to aminoglycosides and their postantibiotic effects. *Antimicrob. Agents Chemother.* 40, 35–39.
- Yamane, K. (2010) 'Biapenem', in Grayson, M. (ed.) *Kucers' The Use Of Antibiotics*. 6th edn. London: Edward Arnold(Publisher) Ltd, p. 543.
- Yazdeli M, 2018, 'Prevalence of class 1, 2 and 3 integrons among multidrug-resistant *Pseudomonas aeruginosa* in Yazd, Iran', *Iran J Microbiol.* 2018 Oct;10(5):300-306
- Zhang, L., Li, X. Z., and Poole, K. (2001). Fluoroquinolone susceptibilities of effluxmediated multidrug-resistant *Pseudomonas aeruginosa*, *Stenotrophomonas maltophilia* and *Burkholderia cepacia*. *J. Antimicrob. Chemother.* 48, 549–552. doi: 10.1093/jac/48.4.549

Zhanel, G., Wiebe, R., Dilay, L. et al. (2007) 'Comparative review Of The carbapenems',  
Drugs, 67(7), pp. 1027-52. Available  
at:<https://www.ncbi.nlm.nih.gov/pubmed/17488146>.